# The Journal of Prevention of Alzheimer s Disease

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/the-journal-of-prevention-of-alzheimer-s-disease/

## Facts

| Field | Value |
| --- | --- |
| Open Access | true |
| ISSN-L | 2274-5807 |
| ISSNs | 2274-5807,2426-0266 |
| OpenAlex ID | https://openalex.org/S4210234663 |
| Publisher | Springer Science+Business Media |

## Journal papers

- [The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention](https://scholariq.org/papers/the-epidemiology-of-alzheimer-s-disease-modifiable-risk-factors-and-prevention/)
- [Early Detection of Mild Cognitive Impairment (MCI) in Primary Care](https://scholariq.org/papers/early-detection-of-mild-cognitive-impairment-mci-in-primary-care/)
- [Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population](https://scholariq.org/papers/detection-rates-of-mild-cognitive-impairment-in-primary-care-for-the-united/)
- [Strong Relationship between Malnutrition and Cognitive Frailty in the Singapore Longitudinal Ageing Studies (SLAS-1 and SLAS-2)](https://scholariq.org/papers/strong-relationship-between-malnutrition-and-cognitive-frailty-in-the-singapore/)
- [Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred](https://scholariq.org/papers/biological-and-cognitive-markers-of-presenilin1-e280a-autosomal-dominant/)
- [A Machine Learning Framework for Assessment of Cognitive and Functional Impairments in Alzheimer's Disease: Data Preprocessing and Analysis](https://scholariq.org/papers/a-machine-learning-framework-for-assessment-of-cognitive-and-functional/)
- [Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research](https://scholariq.org/papers/use-of-lecanemab-and-donanemab-in-the-canadian-healthcare-system-evidence/)
- [Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment](https://scholariq.org/papers/optimising-alzheimer-s-disease-diagnosis-and-treatment-assessing-cost-utility-of-2/)
- [Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease](https://scholariq.org/papers/point-of-view-challenges-in-implementation-of-new-immunotherapies-for-alzheimer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.